Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Shares Sold by AlphaCentric Advisors LLC

AlphaCentric Advisors LLC cut its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 29.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 45,000 shares of the company's stock after selling 19,000 shares during the quarter. Mirum Pharmaceuticals accounts for approximately 1.3% of AlphaCentric Advisors LLC's holdings, making the stock its 23rd biggest position. AlphaCentric Advisors LLC owned approximately 0.09% of Mirum Pharmaceuticals worth $1,755,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Rice Hall James & Associates LLC lifted its holdings in shares of Mirum Pharmaceuticals by 5.7% in the 3rd quarter. Rice Hall James & Associates LLC now owns 242,711 shares of the company's stock valued at $9,466,000 after buying an additional 12,981 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in Mirum Pharmaceuticals by 65.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,176 shares of the company's stock valued at $358,000 after acquiring an additional 3,639 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Mirum Pharmaceuticals by 22.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company's stock valued at $67,000 after acquiring an additional 318 shares during the period. Values First Advisors Inc. boosted its position in shares of Mirum Pharmaceuticals by 20.1% during the 3rd quarter. Values First Advisors Inc. now owns 23,725 shares of the company's stock worth $925,000 after purchasing an additional 3,971 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. grew its stake in shares of Mirum Pharmaceuticals by 10.8% during the 3rd quarter. Hennion & Walsh Asset Management Inc. now owns 116,054 shares of the company's stock worth $4,526,000 after purchasing an additional 11,284 shares during the period.

Analyst Ratings Changes

MIRM has been the topic of several recent analyst reports. Leerink Partners upped their target price on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an "outperform" rating in a research report on Thursday, October 17th. Evercore ISI lifted their price objective on Mirum Pharmaceuticals from $62.00 to $66.00 and gave the stock an "outperform" rating in a report on Thursday, August 8th. HC Wainwright reissued a "buy" rating and issued a $66.00 target price on shares of Mirum Pharmaceuticals in a report on Friday, October 11th. Cantor Fitzgerald lifted their price target on Mirum Pharmaceuticals from $50.00 to $60.00 and gave the stock an "overweight" rating in a research note on Thursday, August 8th. Finally, Robert W. Baird increased their price objective on shares of Mirum Pharmaceuticals from $39.00 to $44.00 and gave the company an "outperform" rating in a research note on Thursday, August 8th. Ten equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $56.82.

Mirum Pharmaceuticals Trading Up 0.8 %

Shares of NASDAQ MIRM traded up $0.33 on Tuesday, reaching $40.78. 199,005 shares of the company traded hands, compared to its average volume of 561,022. The company has a 50 day moving average of $40.10 and a 200 day moving average of $35.00. The company has a current ratio of 3.28, a quick ratio of 3.09 and a debt-to-equity ratio of 1.34. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $23.14 and a fifty-two week high of $45.23. The stock has a market capitalization of $1.95 billion, a PE ratio of -17.66 and a beta of 1.16.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.05). Mirum Pharmaceuticals had a negative net margin of 40.34% and a negative return on equity of 43.47%. The company had revenue of $77.90 million for the quarter, compared to analysts' expectations of $75.03 million. During the same period in the prior year, the firm earned ($0.92) earnings per share. The firm's quarterly revenue was up 107.7% on a year-over-year basis. On average, equities research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.84 earnings per share for the current fiscal year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.